This article is more than 5 years old. Information may no longer be current.

VIDEO: Ipsen presentations spotlight cabozantinib’s potential in hepatocellular carcinoma, gastrointestinal stromal tumor

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Alexandre Lebeaut, MD, head of research and development at Ipsen Pharmaceuticals, spoke with HemOnc Today at ASCO Annual Meeting about key study results the company presented and promising investigational agents in its pipeline.

ASCO presentations spotlighted data from trials that evaluated cabozantinib (Cabometyx) for patients with advanced hepatocellular carcinoma or metastatic gastrointestinal stromal tumor. Other abstracts focused on use of liposomal irinotecan injection for patients with small cell lung cancer, and the use of lanreotide autogel for treatment of clinical symptoms associated with inoperable malignant intestinal obstruction.